38240 coverage policies: Medicare and commercial payers

14 active Medicare policies list 38240, and 92 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.

Get free alerts for 38240

Free account. Policy pages stay open to everyone.

Medicare policies listing 38240

LCD · NGS-J6-L39513

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin and Non-Hodgkin Lymphoma with B-cell or T-cell Origin

J6 · Effective Aug 1, 2023

LCD · NGS-JK-L39513

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin and Non-Hodgkin Lymphoma with B-cell or T-cell Origin

JK · Effective Aug 1, 2023

LCD · CGS-J15-L39434

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

J15 · Effective Feb 19, 2023

LCD · NORIDIAN-JE-L39396

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

JE · Effective Mar 5, 2023

LCD · NORIDIAN-JF-L39396

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

JF · Effective Mar 5, 2023

LCD · PALMETTO-JJ-L39270

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

JJ · Effective Sep 4, 2022

LCD · PALMETTO-JM-L39270

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

JM · Effective Sep 4, 2022

LCD · WPS-J5-L39477

Commercial payer policies listing 38240

92 policies from 9 payers

Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.

BCBS Illinois

Showing 10 of 15 · All BCBS Illinois policies

BCBS Illinois policies listing 38240, with the code’s status in each
Policy	Effective	Status of 38240
Hematopoietic Cell Transplantation for Acute Lymphoblastic LeukemiaPayerPolicy · BCBSIL-SUR703.043	Sep 1, 2026	Covered
Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaPayerPolicy · BCBSIL-SUR703.037	Aug 15, 2026	Covered
Hematopoietic Cell Transplantation for Breast CancerPayerPolicy · BCBSIL-SUR703.038	May 1, 2026	Covered
Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)PayerPolicy · BCBSIL-SUR703.029	May 15, 2026	Covered
Hematopoietic Cell Transplantation for Chronic Myeloid LeukemiaPayerPolicy · BCBSIL-SUR703.041	Jun 15, 2026	Covered

Policy	Effective	Status of 38240
Alzheimer's Disease: Experimental, Investigational, or Unproven TreatmentsPayerPolicy · AETNA-CPB-0788	Feb 20, 2024	Covered
Erythropoiesis Stimulating AgentsPayerPolicy · AETNA-CPB-0195	Jan 9, 2024	Covered
Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous IndicationsPayerPolicy · AETNA-CPB-0606	Aug 31, 2023	Covered
Hematopoietic Cell Transplantation for Chronic Myelogenous LeukemiaPayerPolicy · AETNA-CPB-0674	Sep 19, 2023	Covered
Hematopoietic Cell Transplantation for Multiple MyelomaPayerPolicy · AETNA-CPB-0497	Dec 13, 2023	Covered
Hematopoietic Cell Transplantation for Ovarian CancerPayerPolicy · AETNA-CPB-0635	Sep 13, 2023	Covered
Hematopoietic Cell Transplantation for Selected Childhood Solid TumorsPayerPolicy · AETNA-CPB-0496	Jul 18, 2023	Covered
Hematopoietic Cell Transplantation for Testicular CancerPayerPolicy · AETNA-CPB-0617	Sep 11, 2023	Covered
Huntington's DiseasePayerPolicy · AETNA-CPB-0614	Sep 12, 2023	Covered
Hypertrophic Scars and KeloidsPayerPolicy · AETNA-CPB-0389	Jun 22, 2023	Covered

Policy	Effective	Status of 38240
Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired AnemiasPayerPolicy · REGENCE-TRA45.25	May 1, 2026	Covered
Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaPayerPolicy · REGENCE-TRA45.35	Jan 1, 2026	Covered
Hematopoietic Cell Transplantation for Chronic Myelogenous LeukemiaPayerPolicy · REGENCE-TRA45.31	Dec 1, 2025	Covered
Hematopoietic Cell Transplantation for Hodgkin LymphomaPayerPolicy · REGENCE-TRA45.30	Dec 1, 2025	Covered
Hematopoietic Cell Transplantation for Light-Chain (AL) Amyloidosis or Waldenström MacroglobulinemiaPayerPolicy · REGENCE-TRA45.40	Aug 1, 2026	Covered
Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in AdultsPayerPolicy · REGENCE-TRA45.27	May 1, 2026	Covered
Hematopoietic Cell Transplantation for Multiple Myeloma and POEMS SyndromePayerPolicy · REGENCE-TRA45.22	Dec 1, 2025	Covered
Hematopoietic Cell Transplantation for Non-Hodgkin's LymphomasPayerPolicy · REGENCE-TRA45.23	Mar 1, 2026	Covered
Hematopoietic Cell Transplantation for Solid Tumors of ChildhoodPayerPolicy · REGENCE-TRA45.37	Dec 1, 2025	Covered
Hematopoietic Cell Transplantation in the Treatment of Germ-Cell TumorsPayerPolicy · REGENCE-TRA45.38	Dec 1, 2025	Covered

Policy	Effective	Status of 38240
Hematopoietic Stem Cell Transplantation for Autoimmune Disease and Miscellaneous Solid TumorsPayerPolicy · ANTHEM-TRANS.00031	Jul 1, 2026	Covered
Hematopoietic Stem Cell Transplantation for Diabetes MellitusPayerPolicy · ANTHEM-TRANS.00034	Jan 6, 2026	Not covered
Hematopoietic Stem Cell Transplantation for Genetic Diseases and Aplastic AnemiasPayerPolicy · ANTHEM-TRANS.00029	May 28, 2026	Covered
Hematopoietic Stem Cell Transplantation for Germ Cell TumorsPayerPolicy · ANTHEM-TRANS.00030	Jan 6, 2026	Covered
Hematopoietic Stem Cell Transplantation for Multiple Myeloma and Other Plasma Cell DyscrasiasPayerPolicy · ANTHEM-TRANS.00023	Jan 6, 2026	Covered
Hematopoietic Stem Cell Transplantation for Pediatric Solid TumorsPayerPolicy · ANTHEM-TRANS.00027	Jan 6, 2026	Covered

38240 coverage policies: Medicare and commercial payers

Medicare policies listing 38240

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin and Non-Hodgkin Lymphoma with B-cell or T-cell Origin

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin and Non-Hodgkin Lymphoma with B-cell or T-cell Origin

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Commercial payer policies listing 38240

BCBS Illinois

38240 coverage policies: Medicare and commercial payers

Medicare policies listing 38240

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin and Non-Hodgkin Lymphoma with B-cell or T-cell Origin

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin and Non-Hodgkin Lymphoma with B-cell or T-cell Origin

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Commercial payer policies listing 38240

BCBS Illinois

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Billing and Coding: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin and Non-Hodgkin Lymphoma with B-cell or T-cell Origin

Billing and Coding: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Billing and Coding: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Billing and Coding: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Billing and Coding: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

BCBS Montana

BCBS New Mexico

BCBS Oklahoma

Aetna

Regence BCBS

Anthem

Ambetter

Cigna

Policy	Effective	Status of 38240
Allogeneic Hematopoietic Cell Transplants for Sickle Cell Anemia and β-ThalassemiaPayerPolicy · AMBETTER-CP-MP-108	Not recorded	Covered
Nonmyeloablative Allogeneic Stem Cell TransplantsPayerPolicy · AMBETTER-CP-MP-141	Not recorded	Covered
Tandem TransplantPayerPolicy · AMBETTER-CP-MP-162	Not recorded	Covered